Answers are grounded in this paper and cite their sources.
In this meta-analysis, the use of once-weekly subcutaneous retatrutide was associated with a significant reduction in body weight and improvement of metabolic markers in patients with overweight, obesity and/or T2D, compared with placebo, with an increase in non-severe gastrointestinal and hypersensitivity adverse events. Phase 3 RCTs are expected to shed further light on the efficacy and safety of once-weekly subcutaneous retatrutide over the long term.
No takes yet. Share an insight, caveat, or question.
Pasqualotto et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: